{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-essential-documents-after-trial-ich-e6-section-8”
},
“headline”: “SOP for Essential Documents After Trial (ICH E6 §8)”,
“description”: “This SOP defines the procedures for collecting, filing, and archiving essential documents required after the completion of a clinical trial, in compliance with ICH E6 §8, FDA, EMA, CDSCO, and WHO GCP requirements. It covers trial closeout reports, clinical study reports, IP destruction certificates, financial reconciliations, and archiving processes.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Essential Documents After Trial (ICH E6 §8)

Purpose

The purpose of this SOP is to define standardized procedures for collecting, filing, and archiving essential documents after the completion of a clinical trial. These records demonstrate that the trial was conducted in compliance with GCP, regulatory requirements, and ethical standards, and that data generated is credible and verifiable.

Scope

This SOP applies to sponsors, CROs, investigators, QA, and TMF administrators involved in the closeout, filing, and archiving of essential trial documents. It covers site closeout, final trial reporting, investigational product (IP) destruction, financial reconciliation, and TMF/ISF archiving.

Responsibilities

• Sponsor: Ensures all essential documents are filed, reconciled, and archived.
• CRO: May handle closeout activities under sponsor oversight.
• Investigator: Provides final subject-level records and site closeout report.
• QA: Audits TMF and ISF for completeness at closeout.
• TMF Administrator: Reconciles and files documents, coordinates archiving.
• Regulatory Affairs: Submits final reports to authorities and ECs.

Accountability

The sponsor is accountable for the completeness and retention of essential documents after the trial. The PI is accountable for site-level closeout documentation. QA is accountable for verifying inspection readiness before archiving.

Procedure

1. Site Closeout Documentation
1.1 File Site Closeout Visit Report prepared by CRA.
1.2 File Investigator’s Final Report/Letter of Completion to EC/IRB.
1.3 File EC/IRB notification of trial closure.

2. Final Clinical Trial Reports
2.1 File Clinical Study Report (CSR) prepared per ICH E3 guidelines.
2.2 File statistical analysis reports and listings.
2.3 File data transfer certificates and database lock confirmation.

3. Investigational Product Documentation
3.1 File IP accountability reconciliation logs.
3.2 File IP destruction certificates signed by pharmacist and witness.
3.3 File correspondence regarding IP return or destruction.

4. Safety Documentation
4.1 File final SAE/SUSAR listings.
4.2 File final DSUR/PSUR submissions.
4.3 File pharmacovigilance closeout summary.

5. Financial and Administrative Documentation
5.1 File final financial reconciliation records.
5.2 File final CRO/vendor invoices and payment records.
5.3 File insurance documentation covering trial period.

6. Subject Documentation
6.1 File final subject status logs (completed, withdrawn, lost to follow-up).
6.2 File subject compensation/reimbursement records.

7. Archiving
7.1 TMF/ISF must be reconciled and complete before archiving.
7.2 Archive essential documents in secure, access-controlled facility.
7.3 Retain for a minimum of 15 years or per jurisdictional requirement.
7.4 Document archiving in TMF Archiving Log (Annexure-1).

Abbreviations

• SOP: Standard Operating Procedure
• TMF/ISF: Trial Master File / Investigator Site File
• PI: Principal Investigator
• CRA: Clinical Research Associate
• CSR: Clinical Study Report
• IP: Investigational Product
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• DSUR/PSUR: Development Safety Update Report / Periodic Safety Update Report

Documents

1. TMF Archiving Log (Annexure-1)
2. Site Closeout Checklist (Annexure-2)
3. IP Destruction Certificate (Annexure-3)
4. Final Subject Status Log (Annexure-4)
5. Financial Reconciliation Log (Annexure-5)

References

• ICH E6(R2/R3) – Essential Documents After Trial
• FDA – TMF and Clinical Trial Documentation
• EMA – Post-Trial Documentation Guidance
• CDSCO – Clinical Trial Closure Requirements
• WHO – Archiving and Retention of Essential Documents

Version: 1.0

Approval Section

Annexures

Annexure-1: TMF Archiving Log

Annexure-2: Site Closeout Checklist

Annexure-3: IP Destruction Certificate

Annexure-4: Final Subject Status Log

Annexure-5: Financial Reconciliation Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-IP-Returns-and-Destruction”
},
“headline”: “SOP for IP Returns and Destruction in Clinical Trials”,
“description”: “This SOP defines standardized procedures for investigational product (IP) returns and destruction in clinical trials, ensuring accountability, compliance with ICH GCP, and adherence to FDA, EMA, CDSCO, and WHO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for IP Returns and Destruction

Purpose

The purpose of this SOP is to establish procedures for the return and destruction of investigational products (IP) used in clinical trials. This ensures unused, expired, or damaged IP is managed responsibly, maintaining compliance with ethical, regulatory, and environmental standards.

Scope

This SOP applies to all clinical trial staff including investigators, pharmacists, coordinators, CROs, and sponsors involved in IP return, reconciliation, and destruction processes. It covers on-site destruction, sponsor return shipments, and third-party destruction with certification.

Responsibilities

• Principal Investigator (PI): Ensures IP returns and destruction follow approved procedures and are documented.
• Pharmacist/Authorized Designee: Manages IP reconciliation, prepares for return or destruction, and maintains logs.
• Study Coordinator: Files all destruction and return documentation in ISF and TMF.
• Sponsor/CRO: Authorizes destruction or arranges for IP return to sponsor-designated facilities.
• Quality Assurance Officer: Verifies IP destruction certificates and return logs during audits.

Accountability

The PI is accountable for ensuring investigational product returns and destruction are performed ethically, safely, and in compliance with ICH GCP, national regulations, and sponsor instructions.

Procedure

1. Preparation for IP Return/Destruction
Identify IP for return or destruction (unused, expired, or damaged).
Verify quantities against IP accountability records.
Segregate and label products for return or destruction.

2. IP Returns
Prepare Return Shipment Log (Annexure-1) including batch numbers, expiry dates, and quantities.
Package IP securely and ship to sponsor-designated location.
Maintain courier receipts and sponsor acknowledgment.

3. On-Site Destruction
Conduct destruction only after sponsor authorization.
Use methods compliant with local regulations (e.g., incineration).
Complete Certificate of Destruction (Annexure-2).

4. Third-Party Destruction
Engage licensed vendors authorized for pharmaceutical waste disposal.
Ensure witness of destruction by site or sponsor representative.
File destruction certificate in ISF and TMF.

5. Documentation
Record all activities in IP Return/Destruction Log (Annexure-3).
File approvals, shipment records, and certificates in ISF and TMF.

6. Archiving
Retain records for at least 5 years post-trial or as per national requirements.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• IP: Investigational Product
• CRO: Clinical Research Organization
• ISF: Investigator Site File
• TMF: Trial Master File
• QA: Quality Assurance

Documents

1. Return Shipment Log (Annexure-1)
2. Certificate of Destruction (Annexure-2)
3. IP Return/Destruction Log (Annexure-3)

References

• ICH E6(R2) – Good Clinical Practice
• US FDA – Clinical Trial Guidance
• EMA Clinical Trial Regulation
• CDSCO Clinical Trial Rules, 2019
• WHO – Pharmaceutical Waste and Destruction Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: Return Shipment Log

Annexure-2: Certificate of Destruction

Annexure-3: IP Return/Destruction Log

Revision History

For more SOPs visit: Pharma SOP